Media

  • Jan 4, 2023

    Anti-COVID19 prophylactic paper published in October 2021 already downloaded over 3600 times

  • Jul 28, 2022

    Berwyn-Based Pharmaceutical Company Takes Over-the-Counter Route for Approval of Its New Drug Candidate

  • Jun 27, 2022

    Chester County pharma firm pivots to OTC strategy for experimental pain drug

  • Apr 27, 2022

    Virpax selects Kindeva Drug Delivery as development partner for Diclofenac pMDI commercialization

  • Mar 29, 2022

    [VIDEO] Virpax appears on 6abc Philadelphia

  • Mar 15, 2022

    Virpax shares rise on expanded licensing deal for experimental drug

  • Mar 4, 2022

    ThinkEquity Initiates Coverage on Virpax Pharmaceuticals

  • Feb 23, 2022

    Opiate Alternative: As the US opioid crisis continues, there is now significant interest in non-addictive painkillers

  • Feb 15, 2022

    NIH-backed nasal nonaddictive pain prospect clears early test

  • Jan 21, 2022

    Altasciences chosen by Virpax to conduct first-in-human study of Epoladerm™ for chronic pain associated with osteoarthritis of the knee

  • Dec 23, 2021

    Virpax to start clinical trial for knee pain drug candidate

  • Dec 17, 2021

    How Pharma and Academia are Tackling the Opioid Epidemic

  • Dec 9, 2021

    New CBD nasal spray to target seizures in epilepsy

  • Dec 7, 2021

    Virpax to Develop CBD Nasal Spray for Epilepsy

  • Nov 17, 2021

    Pain Management Company Virpax Sees Promise in Potential COVID-19 Antiviral OTC

  • Sep 4, 2020

    Chester County drug developer Virpax working on ‘molecular mask’ to combat Covid-19

  • Dec 3, 2018

    Is Biopharma Still Committed To Its Role In Public Health?

Recent Press Releases

Read the latest investor news about Virpax.

View all

Video Library on YouTube